文献速递心律失常瓣膜病与结构性心脏病

风湿性二尖瓣狭窄患者心房颤动的管理

Management of atrial fibrillation in patients with rheumatic mitral stenosis.
PubMed 文献 · Heart · 2018-02-16

本文综述风湿性二尖瓣狭窄(MS)合并心房颤动(AF)的管理。AF在MS患者中常见,压力负荷导致左心房结构和电重构,AF加重血流动力学障碍并显著增加血栓栓塞风险,对MS自然病史及连合部切开术结局有负面影响。口服抗凝治疗在AF合并MS时 mandatory,无论严重程度和CHA2DS2-VASc评分;中重度MS不推荐非维生素K拮抗剂口服抗凝药;经皮二尖瓣连合部切开术不预防AF发生,但严重症状性MS合并AF时应作为一线治疗,随后讨论心脏复律或消融;需干预的二尖瓣病患者应考虑AF消融,但理想时机和技术因缺乏专门随机试验难以确定。

要点

  • AF合并MS时口服抗凝治疗为强制,不论MS严重程度和CHA2DS2-VASc评分。
  • 中重度MS不推荐使用非维生素K拮抗剂口服抗凝药。
  • 严重症状性MS合并AF时经皮二尖瓣连合部切开术为一线治疗,随后讨论心脏复律或消融。

核心结论

  • AF在风湿性MS患者中常见,加重血流动力学障碍并显著增加血栓栓塞风险,对MS自然病史和连合部切开术结局有负面影响。
  • AF合并MS时口服抗凝治疗为强制,中重度MS不推荐非维生素K拮抗剂口服抗凝药。
  • 经皮二尖瓣连合部切开术不预防AF发生,但严重症状性MS合并AF时应作为一线治疗。

研究设计与样本

  • 综述,检索范围未在摘要中报告。

主要发现

  • 压力负荷导致左心房显著结构和电重构。
  • 持续性AF频率随年龄增加,阵发性无症状AF似乎更常见。
  • AF加重MS血流动力学耐受性并显著增加血栓栓塞事件风险。
  • AF对MS自然病史及连合部切开术后结局有负面影响。
  • 经皮二尖瓣连合部切开术似乎不预防MS中AF的发生。

关键数值与推荐

  • AF合并MS时口服抗凝治疗为强制,不论MS严重程度和CHA2DS2-VASc评分。
  • 中重度MS不推荐非维生素K拮抗剂口服抗凝药,因缺乏数据。
  • 严重症状性MS合并AF时经皮二尖瓣连合部切开术应作为一线治疗,随后讨论心脏复律或消融。
  • 需干预的二尖瓣病患者应考虑AF消融,但理想时机和技术因缺乏专门随机试验难以确定。

临床怎么用

  • AF合并MS患者应启动口服抗凝治疗,不依赖CHA2DS2-VASc评分。
  • 中重度MS患者避免使用非维生素K拮抗剂口服抗凝药。
  • 严重症状性MS合并AF时优先考虑经皮二尖瓣连合部切开术,术后评估心脏复律或消融。
  • 需干预的二尖瓣病患者应考虑AF消融,但时机和技术需个体化。

局限性

  • 缺乏针对MS患者的专门随机试验,AF消融的理想时机和技术难以确定。
  • 中重度MS不推荐非维生素K拮抗剂口服抗凝药是基于缺乏数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Atrial fibrillation (AF) is frequent in patients with rheumatic mitral stenosis (MS). Pressure overload leads to marked structural and electrical remodelling of left atrium. The frequency of persistent AF increases with age and paroxysmal, asymptomatic, AF seems even more frequent. The occurrence of AF worsens the haemodynamic tolerance of MS and markedly increases the risk of thromboembolic events. AF has a negative impact on the natural history of MS and on its outcome after commissurotomy. The respective indications of rhythm and rate control should be adapted to patient characteristics, particularly the consequences of MS, and take into account the high risk of recurrence of AF. Oral anticoagulant therapy is mandatory when AF complicates MS, regardless of its severity and CHA2DS2-VASc score. Non-vitamin K antagonists oral anticoagulants are not recommended in moderate-to-severe MS due to the lack of data. Percutaneous mitral commissurotomy does not appear to prevent the occurrence of AF in MS but should be considered as the first-line therapy when AF is associated with severe symptomatic MS, followed by the discussion of cardioversion or ablation. AF ablation should be considered in patients with mitral disease requiring intervention, but the ideal timing and techniques are difficult to determine due to the lack of appropriate specific randomised trials in patients with MS.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Iung B, Leenhardt A, Extramiana F, et al. Management of atrial fibrillation in patients with rheumatic mitral stenosis. Heart. 2018. PMID: 29453328. doi:10.1136/heartjnl-2017-311425

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。